| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
Myrislignan targets the NF-κB signaling pathway. By inhibiting NF-κB signaling pathway activation, it reduces the expression of pro-inflammatory mediators such as IL-6, TNF-α, iNOS, and COX-2. Myrislignan also inhibits the proliferation of A549 cells in a dose- and time-dependent manner and significantly induces apoptosis and cell cycle arrest in A549 cells.
|
|---|---|
| ln Vitro |
In vitro, myrislignan inhibits IL-6 and TNF-α production. It significantly inhibits the expressions of iNOS and COX-2 in LPS-stimulated macrophage cells. It inhibits the proliferation of A549 cells in a dose- and time-dependent manner and significantly induces apoptosis and cell cycle arrest in A549 cells. Myrislignan attenuates LPS-induced inflammation in murine macrophage cells.
|
| ln Vivo |
In vivo, myrislignan has been reported to possess inhibition of neoplasm and vascular smooth muscle contraction, and cause a prolonging of hexobarbital-induced hypnosis in mice. Its anti-inflammatory and anti-cancer activities suggest potential therapeutic applications. Further in vivo studies are needed to evaluate its efficacy.
|
| Enzyme Assay |
The in vitro NF-κB inhibition assay for myrislignan measures its ability to inhibit NF-κB signaling pathway activation. Cells are treated with myrislignan and stimulated with LPS. NF-κB activation is assessed by measuring the phosphorylation and degradation of IκBα or by using NF-κB reporter gene assays. The expression of NF-κB target genes (IL-6, TNF-α, iNOS, COX-2) is measured by qRT-PCR or ELISA.
|
| Cell Assay |
In vitro cellular studies are conducted using macrophage cells (e.g., RAW 264.7) and cancer cell lines (e.g., A549 lung cancer cells). Cells are treated with myrislignan at various concentrations. Inflammatory cytokine production is measured by ELISA. iNOS and COX-2 expression is measured by Western blot or qRT-PCR. Cell proliferation is assessed using MTT or CellTiter-Glo assays. Apoptosis is measured by Annexin V/PI staining or caspase-3 activity assays.
|
| Animal Protocol |
In vivo animal experiments with myrislignan are limited. The compound is a natural product with potential anti-inflammatory and anti-cancer activities. Further in vivo studies are needed to evaluate its efficacy in models of inflammation and cancer. Animals would be administered myrislignan via injection or oral gavage, and endpoints would include tumor growth inhibition and inflammation reduction.
|
| ADME/Pharmacokinetics |
Myrislignan has a molecular formula of C21H26O6 and a molecular weight of 374.43 g/mol. It is an 8-O-4′ type neolignan isolated from Myristica fragrans Houtt (nutmeg). For storage, it should be kept at -20°C, protected from light and moisture. The compound is supplied with high purity for research purposes. It is a lignan with anti-inflammatory and anti-cancer activities.
|
| Toxicity/Toxicokinetics |
As a research chemical with potent biological activity, myrislignan is not intended for human use. Its toxicological profile is not fully characterized. Standard laboratory safety precautions should be followed when handling it. Its effects are related to its mechanism as an NF-κB inhibitor, which could have anti-inflammatory and anti-cancer effects.
|
| References | |
| Additional Infomation |
Myrislignan is a phenylpropanoid compound. It has been reported that nutmeg (Myristica fragrans) contains Myrislignan, and relevant data are available for reference.
Myrislignan is a lignan isolated from Myristica fragrans Houtt (nutmeg). It has anti-inflammatory and anti-cancer activities. Myrislignan inhibits IL-6 and TNF-α and inhibits iNOS and COX-2 expression. It attenuates LPS-induced inflammation by inhibiting NF-κB signaling pathway activation. It inhibits the proliferation of A549 cells and induces apoptosis and cell cycle arrest. |
| Molecular Formula |
C21H26O6
|
|---|---|
| Molecular Weight |
374.4275
|
| Exact Mass |
374.172
|
| CAS # |
171485-39-5
|
| Related CAS # |
(Rac)-Myrislignan; 41535-95-9; Myrislignan-13C,d2
|
| PubChem CID |
21636106
|
| Appearance |
White to off-white solid powder
|
| Density |
1.167
|
| Boiling Point |
537.6±50.0 °C at 760 mmHg
|
| Flash Point |
278.9±30.1 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.562
|
| Source |
Originated from plants: Myristicaceae Myristica fragrans Houtt.
|
| LogP |
2.54
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
27
|
| Complexity |
430
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C[C@@H]([C@@H](C1=CC(=C(C=C1)O)OC)O)OC2=C(C=C(C=C2OC)CC=C)OC
|
| InChi Key |
ULZFTGWWPHYLGI-RBZFPXEDSA-N
|
| InChi Code |
InChI=1S/C21H26O6/c1-6-7-14-10-18(25-4)21(19(11-14)26-5)27-13(2)20(23)15-8-9-16(22)17(12-15)24-3/h6,8-13,20,22-23H,1,7H2,2-5H3/t13-,20-/m0/s1
|
| Chemical Name |
4-[(1R,2S)-2-(2,6-dimethoxy-4-prop-2-enylphenoxy)-1-hydroxypropyl]-2-methoxyphenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~267.07 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.68 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.68 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.68 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6707 mL | 13.3536 mL | 26.7073 mL | |
| 5 mM | 0.5341 mL | 2.6707 mL | 5.3415 mL | |
| 10 mM | 0.2671 mL | 1.3354 mL | 2.6707 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
